Scarica l'app Stockscreener
20.80
1.98%
-0.42
Pre-mercato:
21.13
0.33
+1.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GMAB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.22
Aprire:
$20.85
Volume 24 ore:
1.10M
Relative Volume:
0.87
Capitalizzazione di mercato:
$13.21B
Reddito:
$2.89B
Utile/perdita netta:
$684.26M
Rapporto P/E:
19.76
EPS:
1.0524
Flusso di cassa netto:
$958.82M
1 W Prestazione:
-6.09%
1M Prestazione:
+3.84%
6M Prestazione:
-22.47%
1 anno Prestazione:
-28.64%
Intervallo 1D:
$20.75
$21.02
Intervallo di 1 settimana:
$19.89
$22.08
Portata 52W:
$19.85
$31.88
Genmab Adr Stock (GMAB) Company Profile
Confronta GMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
20.80 | 13.21B | 2.89B | 684.26M | 958.82M | 1.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Downgrade | Citigroup | Neutral → Sell |
| 2023-12-06 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Aggiornamento | DNB Markets | Sell → Buy |
| 2023-10-18 | Iniziato | Exane BNP Paribas | Underperform |
| 2023-09-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Iniziato | BTIG Research | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-31 | Iniziato | UBS | Neutral |
| 2023-05-12 | Iniziato | Morgan Stanley | Underweight |
| 2022-12-20 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-14 | Iniziato | William Blair | Mkt Perform |
| 2022-11-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-05-02 | Iniziato | Cowen | Market Perform |
| 2022-03-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-12-01 | Iniziato | Berenberg | Sell |
| 2021-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Iniziato | Deutsche Bank | Buy |
| 2021-01-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Downgrade | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-06-25 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Iniziato | Credit Suisse | Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | Morgan Stanley | Overweight |
| 2019-08-12 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Genmab Adr Borsa (GMAB) Ultime notizie
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
GMAB or INCY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
Market Resilience: Genmab ADR (GMAB) Finishes Weak at 24.14, Down -5.44 - The Dwinnex
GANDHIM.APPL Share Price Today Up 13% - Equitymaster
Glenmark Pharma Share Price Today Down 3% - Equitymaster
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - MSN
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls - Yahoo Finance
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Yahoo Finance Australia
RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com
GMAB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
GMAB vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews.com
New Strong Buy Stocks for January 17th - Yahoo Finance
GMAB: 3 Biotech Stocks to Boost Portfolios - StockNews.com
GMAB: 3 Biotech Stocks to Watch in November - StockNews.com
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch
GMAB: 2 Explosive Biotech Stocks to Own - StockNews.com
Stocks Generating Improved Relative Strength: Genmab ADR - Investor's Business Daily
Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark - Inkl
Stock Upgrades: Legend Biotech ADR Shows Rising Relative Strength - Investor's Business Daily
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada
Ascendis Pharma ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Horizon Therapeutics Is A Stock With Rising Relative Strength - Investor's Business Daily
Genmab's chief development officer sells shares in US - MedWatch
Stocks To Watch: Genmab Sees Relative Strength Rating Jump To 82 - Investor's Business Daily
Zealand Pharma to delist in US - MedWatch
Should You Buy Genmab (GMAB) Ahead of Earnings? - Yahoo Finance
Inside Genmab's blockbuster IPO - IR Magazine
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
Emergent BioSolutions Sees Its Composite Rating Rise To 97 - Investor's Business Daily
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug - Yahoo Finance
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO - Benzinga
Genmab's offering and listing in the USA - Bech-Bruun
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus.com
Genmab Adr Azioni (GMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):